Lyell Wealth Management LP maintained its stake in shares of Eli Lilly and Company (NYSE:LLY) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 4,491 shares of the company’s stock at the end of the 2nd quarter. Lyell Wealth Management LP’s holdings in Eli Lilly and were worth $370,000 as of its most recent SEC filing.
A number of other hedge funds also recently made changes to their positions in the business. Vanguard Group Inc. lifted its stake in Eli Lilly and by 3.3% in the 1st quarter. Vanguard Group Inc. now owns 68,597,006 shares of the company’s stock worth $5,769,694,000 after purchasing an additional 2,181,701 shares in the last quarter. BlackRock Inc. lifted its stake in Eli Lilly and by 2,628.5% in the 1st quarter. BlackRock Inc. now owns 62,260,488 shares of the company’s stock worth $5,236,731,000 after purchasing an additional 59,978,664 shares in the last quarter. State Street Corp lifted its stake in Eli Lilly and by 1.6% in the 1st quarter. State Street Corp now owns 42,363,935 shares of the company’s stock worth $3,563,230,000 after purchasing an additional 651,424 shares in the last quarter. Geode Capital Management LLC lifted its stake in Eli Lilly and by 8.4% in the 1st quarter. Geode Capital Management LLC now owns 9,103,975 shares of the company’s stock worth $764,597,000 after purchasing an additional 708,597 shares in the last quarter. Finally, Janus Capital Management LLC lifted its stake in Eli Lilly and by 2.8% in the 1st quarter. Janus Capital Management LLC now owns 8,723,692 shares of the company’s stock worth $733,731,000 after purchasing an additional 237,619 shares in the last quarter. Institutional investors and hedge funds own 75.72% of the company’s stock.
Eli Lilly and Company (LLY) opened at 82.52 on Tuesday. The company has a market capitalization of $87.06 billion, a P/E ratio of 35.71 and a beta of 0.34. The firm has a 50-day moving average of $80.87 and a 200-day moving average of $82.04. Eli Lilly and Company has a 52 week low of $64.18 and a 52 week high of $86.72.
Eli Lilly and (NYSE:LLY) last issued its earnings results on Tuesday, July 25th. The company reported $1.11 EPS for the quarter, topping analysts’ consensus estimates of $1.05 by $0.06. Eli Lilly and had a net margin of 11.12% and a return on equity of 28.71%. The company had revenue of $5.82 billion for the quarter, compared to the consensus estimate of $5.60 billion. During the same period in the previous year, the firm earned $0.86 earnings per share. Eli Lilly and’s quarterly revenue was up 7.8% compared to the same quarter last year. Analysts anticipate that Eli Lilly and Company will post $4.16 EPS for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: This piece of content was originally published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are viewing this piece of content on another publication, it was copied illegally and republished in violation of United States & international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://www.chaffeybreeze.com/2017/09/19/lyell-wealth-management-lp-has-370000-stake-in-eli-lilly-and-company-lly.html.
Several brokerages have commented on LLY. BidaskClub upgraded shares of Eli Lilly and from a “sell” rating to a “hold” rating in a research note on Wednesday, June 14th. Barclays PLC boosted their price target on shares of Eli Lilly and from $85.00 to $90.00 and gave the stock an “overweight” rating in a research note on Tuesday, July 4th. BMO Capital Markets reiterated a “sell” rating and issued a $73.00 price target on shares of Eli Lilly and in a research note on Friday, August 4th. Berenberg Bank restated a “buy” rating and set a $100.00 target price on shares of Eli Lilly and in a research report on Thursday, July 27th. Finally, Jefferies Group LLC restated a “buy” rating and set a $96.00 target price (up from $93.00) on shares of Eli Lilly and in a research report on Thursday, July 13th. Three investment analysts have rated the stock with a sell rating, seven have issued a hold rating and twelve have given a buy rating to the company. Eli Lilly and has an average rating of “Hold” and a consensus target price of $88.27.
In other news, major shareholder Lilly Endowment Inc sold 220,000 shares of the business’s stock in a transaction that occurred on Monday, July 31st. The shares were sold at an average price of $83.09, for a total value of $18,279,800.00. Following the sale, the insider now directly owns 124,049,283 shares of the company’s stock, valued at approximately $10,307,254,924.47. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders sold a total of 800,000 shares of company stock worth $66,281,600 over the last three months. Insiders own 0.20% of the company’s stock.
Eli Lilly and Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.